GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Peter Lynch Fair Value

Aion Therapeutic (XCNQ:AION) Peter Lynch Fair Value : C$-0.13 (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Aion Therapeutic's PEG is 1. Aion Therapeutic's 5-Year TTM EBITDA Growth Rate is 25. Aion Therapeutic's EPS without NRI for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.01. Therefore, the Peter Lynch Fair Value for today is C$-0.13.

As of today (2024-12-13), Aion Therapeutic's share price is C$0.01. Aion Therapeutic's Peter Lynch fair value is C$-0.13. Therefore, Aion Therapeutic's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Aion Therapeutic's Peter Lynch Fair Value or its related term are showing as below:



XCNQ:AION's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.44
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Aion Therapeutic Peter Lynch Fair Value Historical Data

The historical data trend for Aion Therapeutic's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Peter Lynch Fair Value Chart

Aion Therapeutic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Aion Therapeutic Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aion Therapeutic's Peter Lynch Fair Value

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Price-to-Peter-Lynch-Fair-Value falls into.



Aion Therapeutic Peter Lynch Fair Value Calculation

Aion Therapeutic's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-0.005
=-0.13

Aion Therapeutic's EPS without NRI for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Aion Therapeutic  (XCNQ:AION) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Aion Therapeutic's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.01/-0.13
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aion Therapeutic Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.
Executives
Ismail Abdul Fattah Director or Senior Officer of 10% Security Holder
Douglas Craig Wilson Director or Senior Officer of 10% Security Holder
John Graham Simmonds Director, Senior Officer

Aion Therapeutic Headlines

No Headlines